Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

European Psychiatry

Volumn 26, Issue 5, 2011, Pages 313-319

  Ascher Svanum, H ^a   Peng, X ^a   Montgomery, W ^b   Faries, D E ^a   Lawson, A H ^a   Witte, M M ^a   Novick, D ^a   Jemiai, N ^a   Perrin, E ^a   McDonnell, D P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Olanzapine long acting injection; Oral supplementation; Schizophrenia

Indexed keywords

LONG ACTING DRUG; OLANZAPINE;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FUNCTIONAL STATUS; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SHORT COURSE THERAPY; SUPPLEMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; UNEMPLOYMENT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 79960455536     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.03.015     Document Type: Article

References (33)

1. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67:453-460.
2. Barnes T.R., Curson D.A., Liddle P.F., Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 1989, 154:486-491.
3. Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998, 49:196-201.
4. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence 2009, 3:345-355.
5. Davis J.M., Matalon L., Watanabe M.D., Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994, 47:741-773.
6. Detke H.C., McDonnell D., Kane J., Naber D., Sethuraman G., Lin D. Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial. Schizophr Res 2008, 102(1-3 (Suppl. 2)):262-263.
7. Ereshefsky L., Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003, 64(Suppl. 16):18-23.
8. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699.
9. Guy W. ECDEU Assessment manual for psychopharmacology 1976, 338. US Department of Health, Education, and Welfare, Washington, DC, p. 218-22.
10. Guy W. ECDEU Assessment manual for psychopharmacology 1976, 338. US Department of Health, Education, and Welfare, Washington, DC, p. 534-37.
11. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398.
12. Kalali A. Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin 1999, 15:135-137.
13. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66.
14. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160:1125-1132.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
16. Lauriello J., Lambert T., Andersen S., Lin D., Taylor C.C., McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799.
17. Law M.R., Soumerai S.B., Ross-Degnan D., Adams A.S. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69:47-53.
18. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. American Psychiatric Association (APA). Practice Guideline for the treatment of patients with schizophrenia, 2nd Ed. Am J Psychiatry 2004, 161(9):1717-1718.
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
20. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr Res 2005, 79:231-238.
21. Lindenmayer J.P., Eerdekens E., Berry S.A., Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004, 65:1084-1089.
22. Lindenmayer J.P., Khan A., Eerdekens M., Van Hove I., Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007, 17:138-144.
23. McDonnell D.P., Andersen S.W., Detke H.C., Watson S.B. 160-week interim results from an open-label extension trial of olanzapine long-acting injection. Int J Neuropsychopharmacol 2008, 11(Suppl. 1):151.
24. McEvoy J.P. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006, 67(Suppl. 5):15-18.
25. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001, 50:79-88.
26. Olfson M., Marcus S.C., Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007, 33:1379-1387.
27. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997, 54:453-463.
28. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
29. Sun S.X., Liu G.G., Christensen D.B., Fu A.Z. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312.
30. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639.
31. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
32. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
33. West J.C., Marcus S.C., Wilk J., Countis L.M., Regier D.A., Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008, 34:995-1001.